Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Gα oxidation (Q94587156)
Jump to navigation
Jump to search
scientific article published on 12 May 2020
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Gα oxidation |
scientific article published on 12 May 2020 |
Statements
Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Gα oxidation (English)
Carsten Tschöpe
Sophie Van Linthout
Detmar Kolijn
Steffen Pabel
Yanna Tian
Mária Lódi
Albino Carrizzo
Saltanat Zhazykbayeva
Árpád Kovács
Gábor Á Fülöp
Inês Falcão-Pires
Peter H Reusch
Zoltán Papp
Loek van Heerebeek
Carmine Vecchione
Lars S Maier
Michele Ciccarelli
Andreas Mügge
Zsolt Bagi
Samuel Sossalla